Pipeline

Development Stage and Anticipated Milestones TherapeuticIndication AntibodyProgram IND Enabling Phase 1 Phase 2 Phase 3 Rosnilimab(Pathogenic T cell depleter) P2 data throughWeek 12 anticipatedNov./Dec. 2025 ANB033(CD122 antagonist)Focused IR event Oct. 14 Celiac Disease Ulcerative Colitis Rheumatoid Arthritis P1b initiated P1b to initiatein 2026 Inflammatory Disease P2b trial completeFinal data to be presented ata future medical conference Immune Cell Modulators P1 in healthyvolunteers ongoing ANB101(BDCA2 modulator) Inflammatory Disease